News
Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...
UK pharma major AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal ...
Shares in Summit Therapeutics have risen sharply on a report that AstraZeneca is in discussions for a partnership focused on ...
The Manila Times on MSN1h
AstraZeneca eyes licensing lung cancer drugASTRAZENECA is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as $15 billion, Bloomberg News reported on Thursday, citing people familiar with ...
It might be gearing up to pay billions of dollars to participate in a drug program currently in development. AstraZeneca ...
A large, well-capitalized peer is apparently interested in a partnership deal with the company. The media outlet in question ...
Stocks fade as tariff deadline looms large - US President Donald Trump said he plans to start sending letters informing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback